• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与正常卵巢组织相比,原发性和复发性卵巢高级别浆液性癌表现出相似的微小RNA表达模式。

Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue.

作者信息

Nam Eun Ji, Kim Sunghoon, Lee Taek Sang, Kim Hee Jung, Lee Jung Yun, Kim Sang Wun, Kim Jae Hoon, Kim Young Tae

机构信息

Institute of Women's Life Medical Science, Women's Cancer Clinic, Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.

Department of Obstetrics and Gynecology, SMG-SNU Boramae Medical Center, Seoul, Korea.

出版信息

Oncotarget. 2016 Oct 25;7(43):70524-70534. doi: 10.18632/oncotarget.12045.

DOI:10.18632/oncotarget.12045
PMID:27655640
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5342571/
Abstract

Most patients with epithelial ovarian cancer eventually die due to recurrence. However, little is known about the microRNA (miRNA) expression pattern and its involvement in recurrent ovarian cancer. We analyzed miRNA expression profiles related to the recurrence of advanced ovarian high-grade serous carcinoma (HGSC) using miRNA microarrays. Between May 2006 and December 2012, 37 ovarian HGSC patients underwent secondary cyto-debulking surgery at recurrence. Among them, only 8 pairs of primary and recurrent tumor samples were deemed to be adequate for analysis. The expression profiles of primary ovarian HGSC compared with normal ovarian tissue were significantly consistent with those of recurrent ovarian HGSC compared with normal ovarian tissue (correlation coefficient = 0.81, P = 0.0078). Among 31 miRNAs that increased by more than 4-fold in primary tumors compared with normal ovarian tissue, 27 were also significantly increased in recurrent tumor samples. Likewise, among 35 miRNAs that decreased by more than 4-fold in primary tumors compared with normal ovarian tissue, 34 were also significantly decreased in recurrent tumor samples. We identified 60 miRNAs that were significantly increased in recurrent serous ovarian carcinoma compared with primary tumor tissue, including miR-630, miR-370, and miR-575. Additionally, 52 miRNAs were significantly decreased in recurrent samples, including miR-509-3p, miR-514a-3p, and miR-506-3p. Our results demonstrate that primary and recurrent ovarian HGSC displayed similar miRNA expression patterns. Nevertheless, altered miRNA expression could be implicated in the recurrence of ovarian HGSC, and further study is needed to validate these data in independent cases using a homogeneous methodology.

摘要

大多数上皮性卵巢癌患者最终因复发而死亡。然而,关于微小RNA(miRNA)的表达模式及其在复发性卵巢癌中的作用知之甚少。我们使用miRNA微阵列分析了与晚期卵巢高级别浆液性癌(HGSC)复发相关的miRNA表达谱。2006年5月至2012年12月期间,37例卵巢HGSC患者在复发时接受了二次肿瘤细胞减灭术。其中,只有8对原发性和复发性肿瘤样本被认为适合进行分析。原发性卵巢HGSC与正常卵巢组织相比的表达谱,与复发性卵巢HGSC与正常卵巢组织相比的表达谱显著一致(相关系数=0.81,P=0.0078)。与正常卵巢组织相比,原发性肿瘤中增加超过4倍的31种miRNA中,有27种在复发性肿瘤样本中也显著增加。同样,与正常卵巢组织相比,原发性肿瘤中减少超过4倍的35种miRNA中,有34种在复发性肿瘤样本中也显著减少。我们鉴定出60种在复发性浆液性卵巢癌中与原发性肿瘤组织相比显著增加的miRNA,包括miR-630、miR-370和miR-575。此外,52种miRNA在复发性样本中显著减少,包括miR-509-3p、miR-514a-3p和miR-506-3p。我们的结果表明,原发性和复发性卵巢HGSC表现出相似的miRNA表达模式。然而,miRNA表达的改变可能与卵巢HGSC的复发有关,需要进一步研究以使用统一方法在独立病例中验证这些数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b358/5342571/60b9a3c61fda/oncotarget-07-70524-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b358/5342571/d0b433aa95fa/oncotarget-07-70524-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b358/5342571/cd4736e5f653/oncotarget-07-70524-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b358/5342571/865ed3d4e6b2/oncotarget-07-70524-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b358/5342571/8e78fb44b755/oncotarget-07-70524-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b358/5342571/60b9a3c61fda/oncotarget-07-70524-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b358/5342571/d0b433aa95fa/oncotarget-07-70524-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b358/5342571/cd4736e5f653/oncotarget-07-70524-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b358/5342571/865ed3d4e6b2/oncotarget-07-70524-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b358/5342571/8e78fb44b755/oncotarget-07-70524-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b358/5342571/60b9a3c61fda/oncotarget-07-70524-g005.jpg

相似文献

1
Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue.与正常卵巢组织相比,原发性和复发性卵巢高级别浆液性癌表现出相似的微小RNA表达模式。
Oncotarget. 2016 Oct 25;7(43):70524-70534. doi: 10.18632/oncotarget.12045.
2
Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.浆液性和透明细胞卵巢癌的全球 miRNA 表达分析确定了差异表达的 miRNA,包括 miR-200c-3p 作为一个预后标志物。
BMC Cancer. 2014 Feb 11;14:80. doi: 10.1186/1471-2407-14-80.
3
MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.卵巢癌中 microRNA 的表达及其与临床病理特征的相关性。
World J Surg Oncol. 2012 Aug 27;10:174. doi: 10.1186/1477-7819-10-174.
4
Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma.高级别浆液性癌和卵巢透明细胞癌中差异表达的miRNA概况以及miR-510在卵巢癌中的表达
Mol Med Rep. 2015 Dec;12(6):8021-31. doi: 10.3892/mmr.2015.4485. Epub 2015 Oct 26.
5
Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.卵巢癌及输卵管浆液性上皮内癌中MicroRNA-200通路的特征分析
BMC Cancer. 2017 Jun 17;17(1):422. doi: 10.1186/s12885-017-3417-z.
6
MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.卵巢 BRCA1/2 突变型和非突变型高级别浆液性癌的 microRNA 图谱分析。
PLoS One. 2009 Oct 2;4(10):e7314. doi: 10.1371/journal.pone.0007314.
7
Extracellular microRNA profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma.高级别浆液性卵巢癌患者预后预测的细胞外 microRNA 分析。
Cancer Sci. 2021 Dec;112(12):4977-4986. doi: 10.1111/cas.15154. Epub 2021 Oct 19.
8
Characterization of microRNA expression in serous ovarian carcinoma.浆液性卵巢癌中微小RNA表达的特征分析
Int J Mol Med. 2014 Aug;34(2):491-8. doi: 10.3892/ijmm.2014.1813. Epub 2014 Jun 17.
9
Overexpression of microRNA-196b Accelerates Invasiveness of Cancer Cells in Recurrent Epithelial Ovarian Cancer Through Regulation of Homeobox A9.微小RNA-196b的过表达通过调控同源框A9促进复发性上皮性卵巢癌癌细胞的侵袭性。
Cancer Genomics Proteomics. 2017 Mar-Apr;14(2):137-141. doi: 10.21873/cgp.20026.
10
Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.新辅助化疗患者中与生存及药物反应相关的高级别浆液性卵巢癌miRNA种类的鉴定:一项使用配对肿瘤活检的回顾性纵向分析
Ann Oncol. 2016 Apr;27(4):625-34. doi: 10.1093/annonc/mdw007. Epub 2016 Jan 17.

引用本文的文献

1
MiR-575 in Exosomes of Vaginal Discharge Is Downregulated in Ovarian Cancer Patients.卵巢癌患者阴道分泌物外泌体中的MiR-575表达下调。
Cancer Genomics Proteomics. 2025 May-Jun;22(3):382-396. doi: 10.21873/cgp.20508.
2
Role of DNA methylation and non‑coding RNAs expression in pathogenesis, detection, prognosis, and therapy‑resistant ovarian carcinoma (Review).DNA甲基化和非编码RNA表达在卵巢癌发病机制、检测、预后及治疗抵抗中的作用(综述)
Mol Med Rep. 2025 Jun;31(6). doi: 10.3892/mmr.2025.13509. Epub 2025 Apr 4.
3
Reduced Levels of miR-145-3p Drive Cell Cycle Progression in Advanced High-Grade Serous Ovarian Cancer.

本文引用的文献

1
Downregulation of microRNA-630 inhibits cell proliferation and invasion and enhances chemosensitivity in human ovarian carcinoma.微小RNA-630的下调抑制人卵巢癌细胞的增殖和侵袭并增强其化疗敏感性。
Genet Mol Res. 2015 Jul 31;14(3):8766-77. doi: 10.4238/2015.July.31.25.
2
Whole-genome characterization of chemoresistant ovarian cancer.耐药性卵巢癌的全基因组特征分析。
Nature. 2015 May 28;521(7553):489-94. doi: 10.1038/nature14410.
3
Differential MicroRNA Expression Profiles in Primary and Recurrent Epithelial Ovarian Cancer.原发性和复发性上皮性卵巢癌中的差异微小RNA表达谱
miR-145-3p 水平降低促进晚期高级别浆液性卵巢癌的细胞周期进程。
Cells. 2024 Nov 18;13(22):1904. doi: 10.3390/cells13221904.
4
CypA/TAF15/STAT5A/miR-514a-3p feedback loop drives ovarian cancer metastasis.CypA/TAF15/STAT5A/miR-514a-3p 反馈环驱动卵巢癌转移。
Oncogene. 2024 Nov;43(49):3570-3585. doi: 10.1038/s41388-024-03188-w. Epub 2024 Oct 14.
5
Uncovering miRNA-mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of Ovarian Cancer PEO1-OR Cells with the ATR/CHK1 Pathway Inhibitors.揭示与奥拉帕利耐药和卵巢癌细胞 PEO1-OR 再敏化相关的 miRNA-mRNA 调控网络,该通路抑制剂为 ATR/CHK1 通路抑制剂。
Cells. 2024 May 17;13(10):867. doi: 10.3390/cells13100867.
6
MiR-630 Promotes Radioresistance by Induction of Anti-Apoptotic Effect via Nrf2-GPX2 Molecular Axis in Head-Neck Cancer.miR-630 通过 Nrf2-GPX2 分子轴诱导抗凋亡作用促进头颈部癌症的放射抵抗。
Cells. 2023 Dec 17;12(24):2853. doi: 10.3390/cells12242853.
7
MicroRNA miR-30a inhibits cisplatin resistance in ovarian cancer cells through autophagy.微小 RNA miR-30a 通过自噬抑制卵巢癌细胞对顺铂的耐药性。
Bioengineered. 2021 Dec;12(2):10713-10722. doi: 10.1080/21655979.2021.2001989.
8
MiR-425-5p accelerated the proliferation, migration, and invasion of ovarian cancer cells via targeting AFF4.miR-425-5p 通过靶向 AFF4 促进卵巢癌细胞的增殖、迁移和侵袭。
J Ovarian Res. 2021 Oct 22;14(1):138. doi: 10.1186/s13048-021-00894-x.
9
Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance.chrXq27.3微小RNA簇在复发性卵巢透明细胞癌中的表达及其对顺铂耐药性的影响。
Oncogene. 2021 Feb;40(7):1255-1268. doi: 10.1038/s41388-020-01595-3. Epub 2021 Jan 8.
10
Recurrence-Associated Multi-RNA Signature to Predict Disease-Free Survival for Ovarian Cancer Patients.与复发相关的多 RNA 标志物预测卵巢癌患者无病生存。
Biomed Res Int. 2020 Feb 14;2020:1618527. doi: 10.1155/2020/1618527. eCollection 2020.
Anticancer Res. 2015 May;35(5):2611-7.
4
MicroRNA-630 is a prognostic marker for patients with colorectal cancer.微小RNA-630是结直肠癌患者的一个预后标志物。
Tumour Biol. 2014 Oct;35(10):9787-92. doi: 10.1007/s13277-014-2223-3. Epub 2014 Jul 1.
5
Increased microRNA-630 expression in gastric cancer is associated with poor overall survival.胃癌中微小RNA-630表达增加与总体生存率低相关。
PLoS One. 2014 Mar 12;9(3):e90526. doi: 10.1371/journal.pone.0090526. eCollection 2014.
6
Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.下一代测序技术的上皮性卵巢癌综合基因组分析揭示了新的靶向治疗途径。
Gynecol Oncol. 2013 Sep;130(3):554-9. doi: 10.1016/j.ygyno.2013.06.019. Epub 2013 Jun 20.
7
Should studies of maintenance therapy be maintained in women with ovarian cancer?对于卵巢癌女性患者,维持治疗的研究是否应继续进行?
J Gynecol Oncol. 2013 Apr;24(2):105-7. doi: 10.3802/jgo.2013.24.2.105. Epub 2013 Apr 5.
8
Suppression of cancer stemness p21-regulating mRNA and microRNA signatures in recurrent ovarian cancer patient samples.抑制复发性卵巢癌患者样本中的癌症干性 p21 调节 mRNA 和 microRNA 特征。
J Ovarian Res. 2012 Jan 19;5(1):2. doi: 10.1186/1757-2215-5-2.
9
Statistical considerations for analysis of microarray experiments.用于微阵列实验分析的统计考虑因素。
Clin Transl Sci. 2011 Dec;4(6):466-77. doi: 10.1111/j.1752-8062.2011.00309.x. Epub 2011 Nov 7.
10
Integrated genomic analyses of ovarian carcinoma.卵巢癌的综合基因组分析。
Nature. 2011 Jun 29;474(7353):609-15. doi: 10.1038/nature10166.